United Therapeutics company info

What does United Therapeutics do?
United Therapeutics (NASDAQ:UTHR) is a biotechnology company focused on developing and commercializing innovative products to address the unmet medical needs of patients with chronic and life-threatening diseases. With a keen interest in pulmonary arterial hypertension (PAH) and other similar conditions, United Therapeutics is dedicated to pushing the boundaries of science to improve patient outcomes. Their operations span from research and development to the commercialization of unique therapies. Key projects include advancing treatments in lung transplantation and pulmonary diseases, with the objective of expanding therapeutic options and enhancing quality of life for patients. Through their commitment to innovation and patient care, United Therapeutics aims to lead the way in biotechnological advancements and health solutions.
United Therapeutics  company media
Company Snapshot

Is United Therapeutics a public or private company?

key
Ownership
Public

How many people does United Therapeutics employ?

people
Employees
1,078

What sector is United Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for United Therapeutics ?

location pin
Head Office
Silver Spring, United States

What year was United Therapeutics founded?

founded flag
Year Founded
1996
What does United Therapeutics specialise in?
/Pharmaceutical Development /Biotechnology Innovations /Pulmonary Hypertension Treatment /Organ Manufacturing /Disease Research /Medical Technology

What are the products and/or services of United Therapeutics ?

Overview of United Therapeutics offerings
Remodulin (treprostinil) Injection, used to treat pulmonary arterial hypertension (PAH), improves exercise ability and delays disease progression.
Tyvaso (treprostinil) Inhalation Solution, for PAH and pulmonary hypertension associated with interstitial lung disease, enhances exercise capacity.
Adcirca (tadalafil), an oral medication for PAH, helps increase exercise ability.
Unituxin (dinutuximab), an immunotherapy for pediatric high-risk neuroblastoma, improves survival rates.
Orenitram (treprostinil) Extended-Release Tablets, for PAH, aids in improving exercise capacity and delaying clinical worsening.
Implantable System for Remodulin (ISR), a delivery system for Remodulin, enhances patient convenience and treatment adherence for PAH.

Who is in the executive team of United Therapeutics ?

United Therapeutics leadership team
  • Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
    Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
    Founder, Chairman & CEO
  • Mr. Michael I. Benkowitz
    Mr. Michael I. Benkowitz
    President & COO
  • Mr. James C. Edgemond
    Mr. James C. Edgemond
    CFO & Treasurer
  • Mr. Paul A. Mahon J.D.
    Mr. Paul A. Mahon J.D.
    Executive VP, General Counsel & Corporate Secretary
  • Mr. Dewey  Steadman C.F.A.
    Mr. Dewey Steadman C.F.A.
    Head of Investor Relations
  • Ms. Holly  Hobson
    Ms. Holly Hobson
    Associate Vice President of Human Resources
  • Kevin T. Gray
    Kevin T. Gray
    Senior Vice President of Strategic Operations & Logistics
  • Mr. Patrick  Poisson
    Mr. Patrick Poisson
    Executive VP of Technical Operations